Related Experiment Videos

Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory

J H Segars1, M S Marks, S Hirschfeld

  • 1Laboratory of Molecular Growth Regulation, National Institute of Child Health and Human Development, Bethesda, Maryland 20892.

Insights

Retinoid X receptor beta (RXR beta) negatively regulates estrogen-responsive genes in breast cancer cells. RXR beta inhibits estrogen receptor activity through distinct pathways, offering new therapeutic targets.

Area of Science:

  • Molecular Biology
  • Endocrinology
  • Cancer Research

Background:

  • Retinoid X receptor beta (RXR beta) is a nuclear receptor that heterodimerizes with other nuclear receptors.
  • RXR beta binds to hormone response elements, including the estrogen response element (ERE).
  • The role of RXR beta in estrogen-responsive transcription in breast cancer remains to be fully elucidated.

Purpose of the Study:

  • To investigate the regulatory role of RXR beta in estrogen-responsive transcription in breast cancer cells.
  • To determine the mechanism by which RXR beta affects estrogen receptor (ER)-mediated ERE activation.

Main Methods:

  • Transfection of RXR beta and a reporter gene into MCF-7 and MDA-MB-231 breast cancer cell lines.
  • Treatment with estrogen and/or RXR ligands.
  • Reporter gene activity assays.
  • Analysis of DNA-binding activity using deletion mutants and cross-linking studies.

Main Results:

  • Endogenous RXR beta contributes to ERE binding activity in MCF-7 cells.
  • RXR beta inhibited ERE-driven reporter activity in a dose-dependent and element-specific manner.
  • Inhibition occurred independently of RXR ligands and was specific to ER-mediated activation.
  • RXR beta/triiodothyronine receptor alpha heterodimers bind ERE, but another triiodothyronine-independent inhibition pathway exists.

Conclusions:

  • RXR beta negatively regulates estrogen-responsive genes in breast cancer cells.
  • RXR beta employs at least two distinct pathways to inhibit ER-mediated transcription.
  • These findings suggest RXR beta as a potential therapeutic target for breast cancer.

Related Concept Videos